➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Baxter
Mallinckrodt
Moodys
Boehringer Ingelheim

Last Updated: August 4, 2021

DrugPatentWatch Database Preview

GUANFACINE HYDROCHLORIDE Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

Which patents cover Guanfacine Hydrochloride, and when can generic versions of Guanfacine Hydrochloride launch?

Guanfacine Hydrochloride is a drug marketed by Actavis Elizabeth, Apotex, Impax Labs Inc, Mylan, Sandoz Inc, Sun Pharm, Teva Pharms Usa, Twi Pharms, Yichang Humanwell, Amneal Pharm, Epic Pharma Llc, Unichem, and Watson Labs. and is included in fifteen NDAs.

The generic ingredient in GUANFACINE HYDROCHLORIDE is guanfacine hydrochloride. There are seven drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the guanfacine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Guanfacine Hydrochloride

A generic version of GUANFACINE HYDROCHLORIDE was approved as guanfacine hydrochloride by WATSON LABS on October 17th, 1995.

  Free Forever Trial

Drug patent expirations by year for GUANFACINE HYDROCHLORIDE
Recent Clinical Trials for GUANFACINE HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Massachusetts General HospitalPhase 2
University of Alabama at BirminghamN/A
Stanford UniversityPhase 4

See all GUANFACINE HYDROCHLORIDE clinical trials

Pharmacology for GUANFACINE HYDROCHLORIDE
Medical Subject Heading (MeSH) Categories for GUANFACINE HYDROCHLORIDE
Paragraph IV (Patent) Challenges for GUANFACINE HYDROCHLORIDE
Tradename Dosage Ingredient NDA Submissiondate
INTUNIV TABLET, EXTENDED RELEASE;ORAL guanfacine hydrochloride 022037 2009-12-29

US Patents and Regulatory Information for GUANFACINE HYDROCHLORIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan GUANFACINE HYDROCHLORIDE guanfacine hydrochloride TABLET;ORAL 074796-001 Jan 27, 1997 DISCN No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Twi Pharms GUANFACINE HYDROCHLORIDE guanfacine hydrochloride TABLET, EXTENDED RELEASE;ORAL 201408-004 Jun 2, 2015 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Watson Labs GUANFACINE HYDROCHLORIDE guanfacine hydrochloride TABLET;ORAL 074145-001 Oct 17, 1995 AB RX No No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
Baxter
Mallinckrodt
Moodys
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.